Related Experiment Video
Updated: Aug 6, 2026
08:06
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
Published on: January 15, 2010
The apomorphine test in parkinsonian syndromes
D F D'Costa1, R J Abbott, I F Pye
1Department of Neurology, Leicester Royal Infirmary, UK.
Journal of Neurology, Neurosurgery, and Psychiatry
|October 1, 1991
Summary
Apomorphine effectively predicts levodopa response in Parkinson's disease (IPD) and aids in distinguishing it from Parkinsonian plus syndromes (PPS). This dopamine agonist shows high responsiveness in IPD patients.
Area of Science:
- Neurology
- Pharmacology
Background:
- Apomorphine, a dopamine receptor agonist, is utilized for managing Parkinson's disease fluctuations.
- Assessing apomorphine's utility in predicting levodopa responsiveness and differentiating Parkinson's disease subtypes is crucial.
Purpose of the Study:
- To evaluate apomorphine as a predictor of dopa responsiveness in idiopathic Parkinson's disease (IPD).
- To investigate apomorphine's role in differentiating IPD from Parkinsonian plus syndromes (PPS).
Main Methods:
- Twenty IPD patients and eight PPS patients were administered apomorphine after a 12-hour levodopa withdrawal.
- Patient responses were assessed, followed by reassessment after one month of oral levodopa treatment.
Main Results:
- Ninety-five percent of IPD patients (19/20) responded positively to apomorphine.
- Ninety percent of IPD patients (18/20) responded to oral levodopa.
- Twenty-five percent of PPS patients (2/8) responded to apomorphine but not levodopa; severe drowsiness occurred in PPS patients.
Conclusions:
- Apomorphine injection serves as a reliable predictor of dopa responsiveness in IPD.
- The apomorphine test demonstrates potential value in differentiating IPD from PPS, aiding in diagnosis.
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...